The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers

Spending bill passed by the House last week would pay for telemedicine appointments until Dec. 31, 2027, but provides no solution to make coverage permanent.

Wall Street is discovering that the Republican party’s longstanding romance with Medicare Advantage has entered a more complicated chapter.

By Siddhi Mahatole and Amina Niasse Jan 26 (Reuters) - The U.S. has proposed an average rate increase of 0.09% in payments to private insurers next year for the Medicare Advantage plans they manage, the government said on Monday,

Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower prices expected in 2028.

The government has proposed new rules for the nation's transplant system that aim to increase use of certain donated organs and set additional safety standards for donor groups

Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into effect until 2028.

By Deanna Neff HealthDay ReporterTHURSDAY, Jan. 29, 2026 (HealthDay News) — Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of federal price negotiations that could lower prices for Medicare patients.

By Michael Erman and Deena Beasley Jan 27 (Reuters) - The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz.

The program is becoming more expensive and restrictive.